hca519/TPX2: a potential T-cell tumor-associated antigen for human hepatocellular carcinoma

Simple item page
dc.AffiliationOctober University for modern sciences and Arts (MSA)
dc.contributor.authorM Aref, Ahmed
dc.contributor.authorT Hoa, Neil
dc.contributor.authorGe, Lisheng
dc.contributor.authorAgrawal, Anshu
dc.contributor.authorDacosta-Iyer, Maria
dc.contributor.authorLambrecht, Nils
dc.contributor.authorOuyang, Yi
dc.contributor.authorN Cornforth, Andrew
dc.contributor.authorR Jadus, Martin
dc.date.accessioned2019-11-05T06:42:48Z
dc.date.available2019-11-05T06:42:48Z
dc.date.issued2014
dc.description.abstractImmunotherapy for human hepatocellular cancer (HCC) is slowly making progress towards treating these fatal cancers. The identification of new antigens can improve this approach. We describe a possible new antigen, hepatocellular carcinoma‐associated antigen‐519/targeting protein for Xklp‐2 (HCA519/TPX2), for HCC that might be beneficial for T‐cell specific HCC immunotherapy.en_US
dc.description.sponsorshipDove Pressen_US
dc.identifier.citation1. Michielsen PP, Francque SM, van Dongen JL. Viral hepatitis and hepatocellular carcinoma. World J Surg Oncol. 2005;3:27. 2. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol. 2009;27(9):1485–1491. 3. Chang MH, Chen TH, Hsu HM, et al. Prevention of hepatocellular carcinoma by universal vaccination against hepatitis B virus: the effect and problems. Clin Cancer Res. 2005;11(21):7953–7957. 4. Pardee AD, Butterfield LH. Immunotherapy of hepatocellular carcinoma: Unique challenges and clinical opportunities. Oncoimmunology. 2012;1(1):48–55. 5. Buonaguro L, Petrizzo A, Tagliamonte M, Tornesello ML, Buonaguro FM. Challenges in cancer vaccine development for hepatocellular carcinoma. J Hepatol. 2013;59(4):897–903. 6. Forni G, Lollini PL, Musiani P, Colombo MP. Immunoprevention of cancer: is the time ripe? Cancer Res. 2000;60(10):2571–2575. 7. Kimura T, McKolanis JR, Dzubinski LA, et al. MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study. Cancer Prev Res (Phila). 2013;6(1):18–26. 8. Vollmer CM Jr, Eilber FC, Butterfield LH, et al. Alpha-fetoproteinspecific genetic immunotherapy for hepatocellular carcinoma. Cancer Res. 1999;59(13):3064–3067. 9. Chu PG, Ishizawa S, Wu E, Weiss LM. Hepatocyte antigen as a marker of hepatocellular carcinoma: an immunohistochemical comparison to carcinoembryonic antigen, CD10, and alpha-fetoprotein. Am J Surg Pathol. 2002;26(8):978–988. 10. Fujioka M, Nakashima Y, Nakashima O, Kojiro M. Immunohistologic study on the expressions of alpha-fetoprotein and protein induced by vitamin K absence or antagonist II in surgically resected small hepatocellular carcinoma. Hepatology. 2001;34(6):1128–1134. 11. Lavaissiere L, Jia S, Nishiyama M, et al. Overexpression of human aspartyl(asparaginyl)beta-hydroxylase in hepatocellular carcinoma and cholangiocarcinoma. J Clin Invest. 1996;98(6):1313–1323. 12. Shimoda M, Tomimaru Y, Charpentier KP, Safran H, Carlson RI, Wands J. Tumor progression-related transmembrane protein aspartate-betahydroxylase is a target for immunotherapy of hepatocellular carcinoma. J Hepatol. 2012;56(5):1129–1135. 13. Komori H, Nakatsura T, Senju S, et al. Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3- specific immunotherapy of hepatocellular carcinoma. Clin Cancer Res. 2006;12(9):2689–2697. 14. Wang Y, Han KJ, Pang XW, et al. Large scale identification of human hepatocellular carcinoma-associated antigens by autoantibodies. J Immunol. 2002;169(2):1102–1109. 15. Li B, Wang Y, Chen J, Wu H, Chen W. Identification of a new HLA- A*0201-restricted CD8+ T cell epitope from hepatocellular carcinoma- associated antigen HCA587. Clin Exp Immunol. 2005;140(2): 310–319. 16. Ge L, Zhang JG, Samathanam CA, et al. Cytotoxic T cell immunity against the non-immunogenic, murine, hepatocellular carcinoma Hepa1-6 is directed towards the novel alternative form of macrophage colony stimulating factor. Cell Immunol. 2009;259(2):117–127. 17. Covini G, Chan EK, Nishioka M, Morshed SA, Reed SI, Tan EM. Immune response to cyclin B1 in hepatocellular carcinoma. Hepatology. 1997;25(1):75–80. 18. Shao DM, Wang QH, Chen C, et al. N-acetylglucosaminyltransferase V activity in metastatic models of human hepatocellular carcinoma in nude mice. J Exp Clin Cancer Res. 1999;18(3):331–335. 19. Bricard G, Bouzourene H, Martinet O, et al. Naturally acquired MAGE-A10- and SSX-2-specific CD8+ T cell responses in patients with hepatocellular carcinoma. J Immunol. 2005;174(3):1709–1716. 20. Chen Z, Shao JB, Wu W. Expression of A, G and B melanoma antigen genes in human hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2002;1(4):570–573. 21. Nies AT, Konig J, Pfannschmidt M, Klar E, Hofmann WJ, Keppler D. Expression of the multidrug resistance proteins MRP2 and MRP3 in human hepatocellular carcinoma. Int J Cancer. 2001;94(4):492–499. 22. Luo G, Huang S, Xie X, et al. Expression of cancer-testis genes in human hepatocellular carcinomas. Cancer Immun. 2002;2:11. 23. Mizukoshi E, Nakamoto Y, Marukawa Y, et al. Cytotoxic T cell responses to human telomerase reverse transcriptase in patients with hepatocellular carcinoma. Hepatology. 2006;43(6):1284–1294. 24. Ikeguchi M, Ueda T, Sakatani T, Hirooka Y, Kaibara N. Expression of survivin messenger RNA correlates with poor prognosis in patients with hepatocellular carcinoma. Diagn Mol Pathol. 2002;11(1):33–40. 25. Perugorria MJ, Castillo J, Latasa MU, et al. Wilms’ tumor 1 gene expression in hepatocellular carcinoma promotes cell dedifferentiation and resistance to chemotherapy. Cancer Res. 2009;69(4):1358–1367. 26. Zhang JG, Eguchi J, Kruse CA, et al. Antigenic profiles of glioma cells to generate allogeneic vaccines or DC-based therapeutics. Clin Cancer Res. 2007;13:566–575. 27. Ge L, Cornforth AN, Hoa NT, et al. Differential glioma-associated tumor antigen expression profiles of human glioma cells grown in hypoxia. PLoS One. 2012;7(9):e42661. 28. Agrawal S, Gupta S, Agrawal A. Human dendritic cells activated via dectin-1 are efficient at priming Th17, cytotoxic CD8 T and B cell responses. PLoS One. 2010;5(10):e13418. 29. Gordan JD, Vonderheide RH. Universal tumor antigens as targets for immunotherapy. Cytotherapy. 2002;4(4):317–327. 30. Cheever MA, Allison JP, Ferris AS, et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res. 2009;15(17): 5323–5337. 31. Gulley JL, Drake CG. Immunotherapy for prostate cancer: recent advances, lessons learned, and areas for further research. Clin Cancer Res. 2011;17(12):3884–3891. 32. Prins RM, Soto H, Konkankit V, et al. Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clin Cancer Res. 2011;17(6):1603–1615. 33. Pardoll D, Drake C. Immunotherapy earns its spot in the ranks of cancer therapy. J Exp Med. 2012;209(2):201–209. 34. Couzin-Frankel J. Immune therapy steps up the attack. Science. 2010;330(6003):440–443. 35. Lee WC, Wang HC, Hung CF, Huang PF, Lia CR, Chen MF. Vaccination of advanced hepatocellular carcinoma patients with tumor lysate-pulsed dendritic cells: a clinical trial. J Immunother. 2005;28(5):496–504. 36. Bird AW, Hyman AA. Building a spindle of the correct length in human cells requires the interaction between TPX2 and Aurora A. J Cell Biol. 2008;182(2):289–300. 37. Warner SL, Stephens BJ, Nwokenkwo S, et al. Validation of TPX2 as a potential therapeutic target in pancreatic cancer cells. Clin Cancer Res. 2009;15(21):6519–6528. 38. Ma Y, Lin D, Sun W, et al. Expression of targeting protein for xklp2 associated with both malignant transformation of respiratory epithelium and progression of squamous cell lung cancer. Clin Cancer Res. 2006;12(4):1121–1127. 39. Tanaka S, Arii S, Yasen M, et al. Aurora kinase B is a predictive factor for the aggressive recurrence of hepatocellular carcinoma after curative hepatectomy. Br J Surg. 2008;95(5):611–619. 40. Yang CW, Su JY, Tsou AP, et al. Integrative genomics based identification of potential human hepatocarcinogenesis-associated cell cycle regulators: RHAMM as an example. Biochem Biophys Res Commun. 2005;330(2):489–497. 41. Satow R, Shitashige M, Kanai Y, et al. Combined functional genome survey of therapeutic targets for hepatocellular carcinoma. Clin Cancer Res. 2010;16(9):2518–2528en_US
dc.identifier.doihttps://doi.org/10.2147/OTT.S61442
dc.identifier.otherhttps://doi.org/10.2147/OTT.S61442
dc.identifier.urihttps://cutt.ly/grRcFz8
dc.language.isoenen_US
dc.publisherDove Pressen_US
dc.relation.ispartofseriesDove Press;
dc.subjectUniversity for tumor immunityen_US
dc.subjectcytolytic T-cellsen_US
dc.subjectHLA-A2en_US
dc.subjectHCA519/TPX2en_US
dc.titlehca519/TPX2: a potential T-cell tumor-associated antigen for human hepatocellular carcinomaen_US
dc.typeArticleen_US

Files

Original bundle

Now showing 1 - 2 of 2
Thumbnail Image
Name:
avatar_scholar_256.png
Size:
6.31 KB
Format:
Portable Network Graphics
Description:
Download
Thumbnail Image
Name:
ott-7-1061.pdf
Size:
1.5 MB
Format:
Adobe Portable Document Format
Description:
Download

Collections

Faculty of Biotechnology Research Paper